{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Recommendation Formulation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import os\n",
    "import json\n",
    "import logging\n",
    "\n",
    "from utils.General.quicker import Quicker, QuickerData, QuickerStage\n",
    "from utils.Evidence_Assessment.paper import Paper\n",
    "from utils.Evidence_Assessment.outcome import Outcome\n",
    "from utils.Evidence_Assessment.evidence import Evidence\n",
    "from utils.logging import setup_logging\n",
    "\n",
    "setup_logging()\n",
    "\n",
    "# Hyperparameters\n",
    "YOUR_CONFIG_PATH = 'YOUR_CONFIG_PATH' # e.g. 'config\\config.json'\n",
    "YOUR_QUESTION_DECOMPOSTITION_PATH =  'YOUR_QUESTION_DECOMPOSTITION_PATH' # e.g. 'data\\2021ACR RA\\Question_Decomposition'\n",
    "YOUR_LITERATURE_SEARCH_PATH = 'YOUR_LITERATURE_SEARCH_PATH' # e.g. 'data\\2021ACR RA\\Literature_Search'\n",
    "YOUR_STUDY_SELECTION_PATH = 'YOUR_STUDY_SELECTION_PATH' # e.g. 'data\\2021ACR RA\\Study_Selection'\n",
    "YOUR_EVIDENCE_ASSESSMENT_PATH = 'YOUR_EVIDENCE_ASSESSMENT_PATH' # e.g. 'data\\2021ACR RA\\Evidence_Assessment'\n",
    "YOUR_PAPER_LIBRARY_PATH = 'YOUR_PAPER_LIBRARY_PATH' # e.g. 'data\\2021ACR RA\\Paper_Library'\n",
    "YOUR_RECOMMENDATION_FORMATION_PATH = 'YOUR_RECOMMENDATION_FORMATION_PATH' # e.g. 'data\\2021ACR RA\\Recommendation_Formation'\n",
    "\n",
    "\n",
    "disease = 'disease_or_topic_of_your_question' # Disease name or clinical topic of your clinical question. e.g. 'Rheumatoid Arthritis (RA)'\n",
    "pico_idx = \"xxxxxxxxx\" # PICO index of the clinical question, saved in your PICO_Information.json file\n",
    "overall_certainty = \"LOW\" # Overall certainty of the evidence, e.g. \"VERY LOW\", \"LOW\", \"MODERATE\", \"HIGH\". You can determine this based on the evidence assessment results.\n",
    "supplementary_information = '' # Any supplementary information can guide LLM to formulate satisfactory recommendations."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import shutil\n",
    "\n",
    "# move the files from the source directory to the target directory\n",
    "def transfer_outcome_and_paperinfo(source_dir_path, target_dir_path, only_index: str = None):\n",
    "    '''\n",
    "    Transfer the 'outcomeinfo' and 'paperinfo' folders and their subfolders/files from source_dir_path to target_dir_path.\n",
    "    If only_index is provided, only transfer subfolders/files containing '_PICO{only_index}' in their names.\n",
    "\n",
    "    :param source_dir_path: Source directory path\n",
    "    :param target_dir_path: Target directory path\n",
    "    :param only_index: Only transfer subfolders/files containing '_PICO{only_index}' in their names\n",
    "    '''\n",
    "\n",
    "    # Transfer 'outcomeinfo' folder\n",
    "    source_outcomeinfo_path = os.path.join(source_dir_path, 'outcomeinfo')\n",
    "    target_outcomeinfo_path = os.path.join(target_dir_path, 'outcomeinfo')\n",
    "    if os.path.exists(source_outcomeinfo_path):\n",
    "        if only_index:\n",
    "            for item in os.listdir(source_outcomeinfo_path):\n",
    "                if f'_PICO{only_index}' in item:\n",
    "                    source_item_path = os.path.join(source_outcomeinfo_path, item)\n",
    "                    target_item_path = os.path.join(target_outcomeinfo_path, item)\n",
    "                    if os.path.isdir(source_item_path):\n",
    "                        shutil.copytree(source_item_path, target_item_path, dirs_exist_ok=True)\n",
    "                    else:\n",
    "                        os.makedirs(target_outcomeinfo_path, exist_ok=True)\n",
    "                        shutil.copy2(source_item_path, target_item_path)\n",
    "        else:\n",
    "            shutil.copytree(source_outcomeinfo_path, target_outcomeinfo_path, dirs_exist_ok=True)\n",
    "\n",
    "    # Transfer 'paperinfo' folder\n",
    "    source_paperinfo_path = os.path.join(source_dir_path, 'paperinfo')\n",
    "    target_paperinfo_path = os.path.join(target_dir_path, 'paperinfo')\n",
    "    if os.path.exists(source_paperinfo_path):\n",
    "        if only_index:\n",
    "                    for item in os.listdir(source_paperinfo_path):\n",
    "                        if f'_PICO{only_index}' in item:\n",
    "                            source_item_path = os.path.join(source_paperinfo_path, item)\n",
    "                            target_item_path = os.path.join(target_paperinfo_path, item)\n",
    "                            if os.path.isdir(source_item_path):\n",
    "                                shutil.copytree(source_item_path, target_item_path, dirs_exist_ok=True)\n",
    "                            else:\n",
    "                                os.makedirs(target_paperinfo_path, exist_ok=True)\n",
    "                                shutil.copy2(source_item_path, target_item_path)\n",
    "        else:\n",
    "            shutil.copytree(source_paperinfo_path, target_paperinfo_path, dirs_exist_ok=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# The confirmed documents need to be transferred to the recommendation formulation path for subsequent operations. Here is an example code to transfer the files.\n",
    "# transfer_outcome_and_paperinfo(source_dir_path=YOUR_EVIDENCE_ASSESSMENT_PATH,target_dir_path=YOUR_RECOMMENDATION_FORMATION_PATH,only_index=pico_index)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "evidence_assessment_results = {}\n",
    "for file in os.listdir(YOUR_RECOMMENDATION_FORMATION_PATH):\n",
    "    if file.startswith('outcomeinfo_PICO' + pico_idx ) and file.endswith(\n",
    "        '.json'\n",
    "    ):\n",
    "        file_path = os.path.join(YOUR_RECOMMENDATION_FORMATION_PATH, file)\n",
    "        with open(file_path, 'r') as f:\n",
    "            result = json.load(f)\n",
    "\n",
    "        evidence_assessment_results[result[0]['comparator']] = {\n",
    "            \"outcome_list\": result,\n",
    "            \"overall_certainty\": overall_certainty,\n",
    "        }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Quicker: RECOMMENDATION_FORMATION\n",
      "StageState.NOT_STARTED\n",
      "{'disease': 'Rheumatoid Arthritis (RA)', 'clinical_question': 'Should Methotrexate or leflunomide be the first choice for initial treatment of rheumatoid arthritis?', 'pico_idx': 'c3072c89', 'population': '', 'intervention': '', 'comparison': [], 'study': [], 'outcome': {}, 'search_config': {}, 'annotation': {}, 'search_strategy': '', 'search_results': {}, 'inclusion_criteria': '', 'exclusion_criteria': '', 'record_included_studies': [], 'full_text_included_studies': [], 'total_outcome_list': [], 'valid_comparison_list': [], 'outcome_list': [], 'paper_list': [], 'evidence_assessment_results': {'Leflunomide (LEF)': {'outcome_list': [{'outcome_uid': '43b26894', 'clinical_question': 'Should Methotrexate or leflunomide be the first choice for initial treatment of rheumatoid arthritis?', 'population': 'Treatment-na√Øve patients with rheumatoid arthritis', 'intervention': 'Methotrexate (MTX)', 'comparator': 'Leflunomide (LEF)', 'outcome': 'Disease activity (assessed with: ACR 20)', 'importance': 'CRITICAL', 'related_paper_list': ['471ba650', '17e8ec8b', '843ed45e', '2fb5f2ac', '838a2e2f'], 'assessment_results': {'GRADE': {'Study design': 'RANDOMIZED_CONTROLLED_TRIAL', 'Raw data from evidence': {'471ba650': {'data_type': 'Dichotomous Data', 'the number of participants in the intervention groups': {'extracted_data': ['180'], 'original_text_content': ['This 52-week, multicenter, double-blind, controlled trial compared responses to the Health Assessment Questionnaire (HAQ), modified Health Assessment Questionnaire (MHAQ), Problem Elicitation Technique (PET), Medical Outcomes Study Short Form 36 (SF-36), and questions regarding work productivity among 3 treatment groups (leflunomide, methotrexate, and placebo).', 'A total of 482 patients were enrolled, and 480 (182 leflunomide, 118 placebo, and 180 methotrexate) were evaluable for clinical response using a modified intention-to-treat analysis, which was defined as inclusion of all patients who received at least 1 dose of study drug with at least 1 followup visit.']}, 'the number of participants in the comparator groups': {'extracted_data': ['182'], 'original_text_content': ['Statistical analysis. All analyses were performed on the intention-to-treat patient population. Comparisons of baseline and posttreatment values across the 3 treatment groups used chi-square analysis for categorical variables and analysis of variance for continuous variables. The end point of analysis presented herein was 12 months. When necessary, analyses used the last observation carried forward, with all function and health-related quality of life measures required only at month 6 and month 12, or at early termination from the study.', 'A total of 482 patients were enrolled, and 480 (182 leflunomide, 118 placebo, and 180 methotrexate) were evaluable for clinical response using a modified intention-to-treat analysis, which was defined as inclusion of all patients who received at least 1 dose of study drug with at least 1 followup visit.', 'This 52-week, multicenter, doubleblind, controlled trial compared responses to the Health Assessment Questionnaire (HAQ), modified Health Assessment Questionnaire (MHAQ), Problem Elicitation Technique (PET), Medical Outcomes Study Short Form 36 (SF-36), and questions regarding work productivity among 3 treatment groups (leflunomide, methotrexate, and placebo).', 'A total of 482 patients were enrolled, and 480 (182 leflunomide, 118 placebo, and 180 methotrexate) were evaluable for clinical response using a modified intention-to-treat analysis, which was defined as inclusion', 'Participants were divided into three groups: leflunomide (182 subjects), placebo (118 subjects), and methotrexate (18 subjects).']}, 'the number of participants in the intervention groups who did experience the outcome of interest': {'extracted_data': ['46'], 'original_text_content': ['ACR Responder Rates: 20% improvement: Leflunomide achieved a responder rate of 52, methotrexate 46, and placebo 26.', '20% improvement: Leflunomide achieved a responder rate of 52, methotrexate 46, and placebo 26.', 'A total of 482 patients were enrolled, and 480 (182 leflunomide, 118 placebo, and 180 methotrexate) were evaluable for clinical response using a modified intention-to-treat analysis, which was defined as inclusion of all patients who received at least 1 dose of study drug with at least 1 followup visit.', 'ACR response rates in those patients were not different from the response rates in patients whose dose remained at 7.5 mg: 45% and 47%, respectively. This was also true in the leflunomide and placebo treatment groups, in which ACR response rates were 51% in the leflunomide group and 25% in the placebo group among patients whose dose of methotrexate placebo was increased, compared with 53% and 27%, respectively, in patients whose placebo dose remained the same.', 'Comparisons of ’Ü20% and ’Ü50% improvement in the PET weighted top 5 scores (a disease-specific measure), SF-36 physical functioning and bodily pain scales, and physical and mental component scores (a generic measure), in responders and nonresponders (as defined by the ACR criteria of ’Ü20% and ’Ü50% improvement) were examined.']}, 'the number of participants in the intervention groups who did not experience the outcome of interest': {'extracted_data': [], 'original_text_content': ['Because the increase in the weekly dose of methotrexate from 7.5 to 15 mg could occur only in patients who failed to respond, ACR response rates in those patients were not different from the response rates in patients whose dose remained at 7.5 mg: 45% and 47%, respectively.', 'ACR Responder Rates: 20% improvement: Leflunomide achieved a responder rate of 52, methotrexate 46, and placebo 26.', 'Compared with methotrexate, leflunomide administration resulted in significantly (P < 0.01) more improvement in the MHAQ scores, 5 of 8 scales and disability index of the HAQ, weighted top 5 score of the PET, and 2 of 8 scales and physical component score of the SF-36.', 'This was also true in the leflunomide and placebo treatment groups, in which ACR response rates were 51% in the leflunomide group and 25% in the placebo group among patients whose dose of methotrexate placebo was increased, compared with 53% and 27%, respectively, in patients whose placebo dose remained the same.', '- 20% improvement: Leflunomide achieved a responder rate of 52, methotrexate 46, and placebo 26.', 'The table presents the response rates and improvements in various health-related measures for patients with active rheumatoid arthritis undergoing treatment with leflunomide, methotrexate, or placebo as part of a 52-week randomized controlled trial. The measures include the American College of Rheumatology (ACR) responder rates, the Health Assessment Questionnaire (HAQ) disability index, the modified Health Assessment Questionnaire (MHAQ), the Problem Elicitation Technique (PET) top 5 score, the Medical Outcomes Study Short Form 36 (SF-36) physical and mental components, and work productivity.', 'Comparisons of ’Ü20% and ’Ü50% improvement in the PET weighted top 5 scores (a disease-specific measure), SF-36 physical functioning and bodily pain scales, and physical and mental component scores (a generic measure), in responders and nonresponders (as defined by the ACR criteria of ’Ü20% and ’Ü50% improvement) were examined.', '1. **ACR Responder Rates:**', 'Improvements in the PET score, SF-36 physical component score, and work productivity correlated with the ACR responder rates of >20% and >50% improvement.']}, 'the number of participants in the comparator groups who did experience the outcome of interest': {'extracted_data': ['52'], 'original_text_content': ['ACR Responder Rates: 20% improvement: Leflunomide achieved a responder rate of 52, methotrexate 46, and placebo 26.', 'Improvement in the PET top 5 and SF-36 scales and component scores were compared with ACR response rates. Results. Clinically meaningful and statistically significant (P < 0.0001) improvement in measures of function and heath-related quality of life (MHAQ scores, all scales and disability index of the HAQ, weighted top 5 score of the PET, 5 of 8 scales and physical component score of the SF-36, and work productivity) was seen during treatment with leflunomide in comparison with placebo. Methotrexate administration resulted in significant improvements (P < 0.05) in comparison with placebo in the MHAQ scores, HAQ disability index, weighted top 5 score of the PET, physical component score of the SF-36, and bodily pain scale. Compared with methotrexate, leflunomide administration resulted in significantly (P < 0.01) more improvement in the MHAQ scores, 5 of 8 scales and disability index of the HAQ, weighted top 5 score of the PET, and 2 of 8 scales and physical component score of the SF-36. Improvements in the PET score, SF-36 physical component score, and work productivity correlated with the ACR responder rates of >20% and >50% improvement.', '20% improvement: Leflunomide achieved a responder rate of 52, methotrexate 46, and placebo 26.', '1. **ACR Responder Rates:**\\n   - 20% improvement: Leflunomide achieved a responder rate of 52, methotrexate 46, and placebo 26.', 'Comparisons of ’Ü20% and ’Ü50% improvement in the PET weighted top 5 scores (a disease-specific measure), SF-36 physical functioning and bodily pain scales, and physical and mental component scores (a generic measure), in responders and nonresponders (as defined by the ACR criteria of ’Ü20% and ’Ü50% improvement) were examined.']}, 'the number of participants in the comparator groups who did not experience the outcome of interest': {'extracted_data': [], 'original_text_content': ['A total of 482 patients were enrolled, and 480 (182 leflunomide, 118 placebo, and 180 methotrexate) were evaluable for clinical response using a modified intention-to-treat analysis, which was defined as inclusion of all patients who received at least 1 dose of study drug with at least 1 followup visit.', '1. **ACR Responder Rates:**\\n   - 20% improvement: Leflunomide achieved a responder rate of 52, methotrexate 46, and placebo 26.', '- 20% improvement: Leflunomide achieved a responder rate of 52, methotrexate 46, and placebo 26.', 'This report presents a secondary analysis of 438 patients (166 leflunomide, 102 placebo, and 170 methotrexate), all of whom completed baseline and 1 or more followup HAQ and SF-36 questionnaires.', 'Comparisons of ‚â•20% and ‚â•50% improvement in the PET weighted top 5 scores (a disease-specific measure), SF-36 physical functioning and bodily pain scales, and physical and mental component scores (a generic measure), in responders and nonresponders (as defined by the ACR criteria of ‚â•20% and ‚â•50% improvement) were examined.', 'This 52-week, multicenter, double-blind, controlled trial compared responses to the Health Assessment Questionnaire (HAQ), modified Health Assessment Questionnaire (MHAQ), Problem Elicitation Technique (PET), Medical Outcomes Study Short Form 36 (SF-36), and questions regarding work productivity among 3 treatment groups (leflunomide, methotrexate, and placebo). Improvement in the PET top 5 and SF-36 scales and component scores were compared with ACR response rates.', '1. **ACR Responder Rates:**', 'Overall, leflunomide showed greater improvements across most measures compared to methotrexate and placebo, supporting the findings that treatment with leflunomide significantly enhances function and health-related quality of life for RA patients. The trial results indicated that both leflunomide and methotrexate are superior to placebo, with leflunomide slightly outperforming methotrexate in several key metrics.']}}, '17e8ec8b': {'data_type': 'Dichotomous Data', 'the number of participants in the intervention groups': {'extracted_data': ['8'], 'original_text_content': ['Patients and controls. Fifteen patients with active RA according to the American College of Rheumatology (ACR; formerly, the American Rheumatism Association) 1987 criteria (24) were included in a prospective, randomized, double-blind clinical trial comparing leflunomide with methotrexate. After a washout period of 28 days, 7 patients received 20 mg of leflunomide/day (after a loading dose of 100 mg/day for 3 days), and 8 patients received methotrexate 7.5 mg/week, which was increased stepwise to 15 mg/week.', 'After a washout period of 28 days, 7 patients received 20 mg of leflunomide/day (after a loading dose of 100 mg/day for 3 days), and 8 patients received methotrexate 7.5 mg/week, which was increased stepwise to 15 mg/week.', 'The provided table presents demographic and treatment history information for two groups of patients in a clinical trial investigating the effects of leflunomide and methotrexate on rheumatoid arthritis. The study included 7 patients treated with leflunomide and 8 treated with methotrexate.', 'Fifteen patients with active RA according to the American College of Rheumatology (ACR; formerly, the American Rheumatism Association) 1987 criteria (24) were included in a prospective, randomized, doubleblind clinical trial comparing leflunomide with methotrexate.', 'This table is sourced from a prospective, randomized, double-blind clinical trial involving 15 RA patients, aimed at understanding how these treatments influence neutrophil chemotaxis over time.']}, 'the number of participants in the comparator groups': {'extracted_data': ['7'], 'original_text_content': ['After a washout period of 28 days, 7 patients received 20 mg of leflunomide/day (after a loading dose of 100 mg/day for 3 days), and 8 patients received methotrexate 7.5 mg/week, which was increased stepwise to 15 mg/week.', 'The provided table presents demographic and treatment history information for two groups of patients in a clinical trial investigating the effects of leflunomide and methotrexate on rheumatoid arthritis. The study included 7 patients treated with leflunomide and 8 treated with methotrexate.', 'Fifteen patients with active RA according to the American College of Rheumatology (ACR; formerly, the American Rheumatism Association) 1987 criteria (24) were included in a prospective, randomized, double-blind clinical trial comparing leflunomide with methotrexate.', 'Fifteen patients with active RA according to the American College of Rheumatology (ACR; formerly, the American Rheumatism Association) 1987 criteria (24) were included in a prospective, randomized, doubleblind clinical trial comparing leflunomide with methotrexate.', 'This table is sourced from a prospective, randomized, double-blind clinical trial involving 15 RA patients, aimed at understanding how these treatments influence neutrophil chemotaxis over time.']}, 'the number of participants in the intervention groups who did experience the outcome of interest': {'extracted_data': ['6'], 'original_text_content': ['At 4 months, the leflunomide-treated patients showed 67%, 47%, and 54% changes in the TJC, SJC, and CRP values. Corresponding numbers for the methotrexate-treated patients were 29%, 25%, and 18%, respectively.', 'After 4 months, the leflunomide-treated patients showed 67%, 47%, and 54% changes in the TJC, SJC, and CRP values. Corresponding numbers for the methotrexate-treated patients were 29%, 25%, and 18%, respectively.', 'Regarding responder status, categories are organized into non-responder, ACR 20% response, and ACR 50% response rates across the treatment periods (4 months and 1 year). For leflunomide, the ACR 20% response shows the number of patients responding at 14 days and one year. The 50% response rate provides similar data, indicating greater improvements over time compared to 20%. Methotrexate shows broader ranges in response rates at the 50% mark during later evaluations.', 'After 1 year of treatment, leflunomide and methotrexate showed similar effects.', 'Demographic and clinical data on the 15 RA patients included in the clinical study are shown in Table 1. The sex and age distribution was similar in the leflunomide-and methotrexate-treated patients. Both treatment groups contained patients with recent-onset disease and longstanding disease, although the methotrexate group tended to have longer disease duration and to have used more DMARDs before the start of the clinical trial. Clinical response and SF analysis. As shown in Table 2, there was active arthritis in multiple joints at baseline. At 4 months, the leflunomide-treated patients showed 67%, 47%, and 54% changes in the TJC, SJC, and CRP values. Corresponding numbers for the methotrexate-treated patients were 29%, 25%, and 18%, respectively. After 1 year of treatment, leflunomide and methotrexate showed similar effects.']}, 'the number of participants in the intervention groups who did not experience the outcome of interest': {'extracted_data': [], 'original_text_content': ['The study included 7 patients treated with leflunomide and 8 treated with methotrexate.', 'The HTML table presents data from a study examining the effects of two treatments, leflunomide and methotrexate, on neutrophil migration in patients with rheumatoid arthritis. This table is sourced from a prospective, randomized, double-blind clinical trial involving 15 RA patients, aimed at understanding how these treatments influence neutrophil chemotaxis over time.', 'Regarding responder status, categories are organized into non-responder, ACR 20% response, and ACR 50% response rates across the treatment periods (4 months and 1 year). For leflunomide, the ACR 20% response shows the number of patients responding at 14 days and one year. The 50% response rate provides similar data, indicating greater improvements over time compared to 20%. Methotrexate shows broader ranges in response rates at the 50% mark during later evaluations.', 'After 1 year of treatment, leflunomide and methotrexate showed similar effects.', \"After 14 days of treatment, SF was undetectable by clinical examination (confirmed by a 'dry tap' on aspiration) in 3 of the 7 patients who received leflunomide, but SF was present in all of the 8 patients who received methotrexate.\"]}, 'the number of participants in the comparator groups who did experience the outcome of interest': {'extracted_data': ['6'], 'original_text_content': ['After a washout period of 28 days, 7 patients received 20 mg of leflunomide/day (after a loading dose of 100 mg/day for 3 days), and 8 patients received methotrexate 7.5 mg/week, which was increased stepwise to 15 mg/week.', 'Patient demographics and baseline characteristics. Demographic and clinical data on the 15 RA patients included in the clinical study are shown in Table 1. The sex and age distribution was similar in the leflunomide-and methotrexate-treated patients. Both treatment groups contained patients with recent-onset disease and longstanding disease, although the methotrexate group tended to have longer disease duration and to have used more DMARDs before the start of the clinical trial. Clinical response and SF analysis. As shown in Table 2, there was active arthritis in multiple joints at baseline. At 4 months, the leflunomide-treated patients showed 67%, 47%, and 54% changes in the TJC, SJC, and CRP values. Corresponding numbers for the methotrexate-treated patients were 29%, 25%, and 18%, respectively. After 1 year of treatment, leflunomide and methotrexate showed similar effects. After 14 days of treatment, SF was undetectable by clinical examination (confirmed by a \"dry tap\" on aspiration) in 3 of the 7 patients who received leflunomide, but SF was present in all of the 8 patients who  3). However, 2 leflunomide-treated patients and 5 methotrexate-treated patients refused knee aspiration at that time. After 4 months of treatment, 5 leflunomide-treated patients and 6 methotrexate-treated patients showed no signs of knee effusion (dry tap). After 1 year of treatment, SF was again undetectable in most patients from both therapy groups (Table 3). The SF neutrophil counts remained relatively high in patients who did not respond to leflunomide or methotrexate treatment.', 'The provided table presents demographic and treatment history information for two groups of patients in a clinical trial investigating the effects of leflunomide and methotrexate on rheumatoid arthritis. The study included 7 patients treated with leflunomide and 8 treated with methotrexate.', 'Regarding responder status, categories are organized into non-responder, ACR 20% response, and ACR 50% response rates across the treatment periods (4 months and 1 year). For leflunomide, the ACR 20% response shows the number of patients responding at 14 days and one year.', 'Fifteen patients with active RA according to the American College of Rheumatology (ACR; formerly, the American Rheumatism Association) 1987 criteria (24) were included in a prospective, randomized, double-blind clinical trial comparing leflunomide with methotrexate.', 'Clinical and laboratory parameters were used to assess improvement according to the ACR criteria (25).', \"Clinical assessment was performed by 1 observer (MCK) at baseline and after 14 days, 4 months, and 1 year. Assessments included a tender joint count (TJC; 28 joints counted, including both knee joints), swollen joint count (SJC; 28 joints counted, including both knee joints), and the patient's and investigator's global assessments of disease activity.\"]}, 'the number of participants in the comparator groups who did not experience the outcome of interest': {'extracted_data': [], 'original_text_content': ['The HTML table presents data from a study examining the effects of two treatments, leflunomide and methotrexate, on neutrophil migration in patients with rheumatoid arthritis. This table is sourced from a prospective, randomized, double-blind clinical trial involving 15 RA patients, aimed at understanding how these treatments influence neutrophil chemotaxis over time.', 'The provided table presents demographic and treatment history information for two groups of patients in a clinical trial investigating the effects of leflunomide and methotrexate on rheumatoid arthritis. The study included 7 patients treated with leflunomide and 8 treated with methotrexate.', 'Regarding responder status, categories are organized into non-responder, ACR 20% response, and ACR 50% response rates across the treatment periods (4 months and 1 year). For leflunomide, the ACR 20% response shows the number of patients responding at 14 days and one year.', \"In the methotrexate group, the patients' ages ranged from 51 to 78, with an average age of 66 years. The gender distribution was 5 male and 3 female patients. The duration of previous DMARDs usage ranged from 5 to 314 months, with each patient having been on an average of 2 DMARDs (range 0-4).\", 'Regarding responder status, categories are organized into non-responder, ACR 20% response, and ACR 50% response rates across the treatment periods (4 months and 1 year). For leflunomide, the ACR 20% response shows the number of patients responding at 14 days and one year. The 50% response rate provides similar data, indicating greater improvements over time compared to 20%. Methotrexate shows broader ranges in response rates at the 50% mark during later evaluations.', \"After 1 year of treatment, leflunomide and methotrexate showed similar effects. After 14 days of treatment, SF was undetectable by clinical examination (confirmed by a 'dry tap' on aspiration) in 3 of the 7 patients who received leflunomide, but SF was present in all of the 8 patients who 3). However, 2 leflunomide-treated patients and 5 methotrexate-treated patients refused knee aspiration at that time. After 4 months of treatment, 5 leflunomide-treated patients and 6 methotrexate-treated patients showed no signs of knee effusion (dry tap). After 1 year of treatment, SF was again undetectable in most patients from both therapy groups (Table 3). The SF neutrophil counts remained relatively high in patients who did not respond to leflunomide or methotrexate treatment.\", \"For the leflunomide group, the patients' ages ranged from 45 to 79, with an average age of 63 years. The gender distribution was 3 male and 4 female patients. The duration of previous disease-modifying antirheumatic drugs (DMARDs) usage, prior to enrolling in the study, ranged from 6 to 59 months, with each patient having been on an average of 1 DMARD (range 0-1).\"]}}, '843ed45e': {'data_type': 'Dichotomous Data', 'the number of participants in the intervention groups': {'extracted_data': ['19'], 'original_text_content': ['In the study titled \"Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis,\" researchers conducted a prospective, randomized, double-blind clinical trial to assess the effects of leflunomide and methotrexate on synovial tissue. The trial included thirty-nine patients across two centers, and paired synovial tissue biopsy samples were collected at baseline and after four months of treatment.', 'Patients. Thirty-nine patients were included in the study; paired synovial biopsy samples were available for 35 of them. One methotrexate-treated patient died during the study due to a myocardial infarction after 4 weeks of treatment, and 1 leflunomide-treated patient refused the second arthroscopy. Baseline synovial tissue biopsy samples from 1 patient in the leflunomide group and 1 patient in the methotrexate group were not assessable. The demographic characteristics of the 2 groups of RA patients were as follows: in the leflunomide group, 9 men and 7 women with a mean age of 60 years (range 35-77 years), a mean disease duration of 38', 'Clinical efficacy. There was similar clinical efficacy of the instituted therapy in the 2 treatment groups, as demonstrated by changes in clinical parameters after 4 months compared with baseline (Table 1). Single exception was the VAS for pain, which was only significantly reduced in the leflunomide patients. Eight of the 16 patients treated with leflunomide (50%) and 10 of the 19 treated with methotrexate (53%) fulfilled the ACR 20% response criteria after 4 months of treatment. Four of the 16 leflunomide-treated patients (25%) and 4 of the 19 methotrexate-treated patients (21%) fulfilled the ACR 50% response criteria after 4 months of treatment.', 'Patients. Thirty-nine patients were included in the study; paired synovial biopsy samples were available for 35 of them. One methotrexate-treated patient died during the study due to a myocardial infarction after 4 weeks of treatment, and 1 leflunomide-treated patient refused the second arthroscopy. Baseline synovial tissue biopsy samples from 1 patient in the leflunomide group and 1 patient in the methotrexate group were not assessable. The demographic characteristics of the 2 groups of RA patients were as follows: in the leflunomide group, 9 men and 7 women with a mean age of 60 years (range 35-77 years), a mean disease duration of 38     Clinical efficacy. There was similar clinical efficacy of the instituted therapy in the 2 treatment groups, as demonstrated by changes in clinical parameters after 4 months compared with baseline (Table 1). Single exception was the VAS for pain, which was only significantly reduced in the leflunomide patients. Eight of the 16 patients treated with leflunomide (50%) and 10 of the 19 treated with methotrexate (53%) fulfilled the ACR 20% response criteria after 4 months of treatment. Four of the 16 leflunomide-treated patients (25%) and 4 of the 19 methotrexate-treated patients (21%) fulfilled the ACR 50% response criteria after 4 months of treatment. Immunohistochemical analysis. The results of the immunohistochemical analysis at baseline and after 4 months are shown in Table 2. Baseline synovial tissue biopsy samples from 1 patient in the leflunomide group and 1 patient in the methotrexate group were not assessable; and these 2 patients were excluded from the immunohistochemical analysis. Cellularity was especially reduced in the lefluno-mide-treated patients (P œΩ 0.05) and remained relatively unchanged in the methotrexate-treated patients. Macrophage numbers were significantly reduced in the synovial sublining (P œΩ 0.05) in the leflunomide-treated patients and in the intimal lining layer (P œΩ 0.05) in the methotrexate-treated', 'Results. Paired synovial tissue sections were available in 35 patients (16 taking leflunomide, 19 taking methotrexate). Both drugs displayed equal clinical efficacy, with 8 leflunomide-treated patients (50%) and 10 methotrexate-treated patients (53%) fulfilling the American College of Rheumatology 20% response criteria. Both compounds showed similar effects on synovial tissue: reduced numbers of macrophages and reduced ICAM-1 and VCAM-1 expression were noted after 4 months of treatment. Both leflunomide-and methotrexate-treated patients exhibited a decreased MMP-1:TIMP-1 ratio in the synovial tissue. In the subset of patients fulfilling the 20% response criteria of the American College of Rheumatology, a more pronounced reduction in the expression of ICAM-1, VCAM-1, IL-1‚ê§, and MMP-1 was found compared with the nonresponders.', \"Patients. During a period of 14 months, 39 patients with active RA (25) were enrolled in a 2-center, prospective, randomized, double-blind, parallel-design clinical trial comparing leflunomide with methotrexate. Active disease was defined as ’Ü6 swollen or tender joints and levels of moderate or worse on the physician's and patient's assessments of disease activity. All patients had at least 1 clinically involved knee joint. Low-dose prednisone (œΩ10 mg/day) and concomitant stable doses of nonsteroidal antiinflammatory drug (NSAID) treatment were allowed. None of the patients had ever taken leflunomide or methotrexate. In patients taking DMARDs, the treatment was stopped followed by a washout phase of 28 days. Patients were randomized to receive either 20 mg/day of leflunomide, with a loading dose of 100 mg/day for the first 3 days, or 7.5 mg/week of methotrexate, increasing stepwise to 15.0 mg/week over 12 weeks. Clinical assessment at baseline and after 16 weeks included a 28-joint count for swelling and tenderness, physician's and patient's assessment of disease activity, duration of morning stiffness, patient's assessment of pain (by visual analog scale [VAS]), and levels of serum C-reactive protein (CRP). Clinical effects of the treatment regimens were calculated using the American College of Rheumatology (ACR) criteria for clinical response (26). All patients gave informed consent, and the study protocol was approved by the Medical Ethics committees of the Leiden University Medical Center and the Leeds University Hospital. Arthroscopy. In all RA patients, arthroscopy was performed under local anesthesia at baseline and after 16 weeks of treatment (in the same knee). A small-bore 2.7-mm arthroscope (Storz, Tuttlingen, Germany) was used for imaging the synovium as well as for the biopsy procedure (27,28). At each arthroscopy, multiple synovial biopsy samples were taken throughout the entire joint, using a 2.0-mm forceps (Storz). If macroscopic variation of\", 'Thirty-nine patients were included in the study; paired synovial biopsy samples were available for 35 of them. One methotrexate-treated patient died during the study due to a myocardial infarction after 4 weeks of treatment, and 1 leflunomide-treated patient refused the second arthroscopy. Baseline synovial tissue biopsy samples from 1 patient in the leflunomide group and 1 patient in the methotrexate group were not assessable. The demographic characteristics of the 2 groups of RA patients were as follows: in the leflunomide group, 9 men and 7 women with a mean age of 60 years (range 35-77 years), a mean disease duration of 38']}, 'the number of participants in the comparator groups': {'extracted_data': ['16'], 'original_text_content': ['Results. Paired synovial tissue sections were available in 35 patients (16 taking leflunomide, 19 taking methotrexate). Both drugs displayed equal clinical efficacy, with 8 leflunomide-treated patients (50%) and 10 methotrexate-treated patients (53%) fulfilling the American College of Rheumatology 20% response criteria.', 'Thirty-nine patients were included in the study; paired synovial biopsy samples were available for 35 of them. One methotrexate-treated patient died during the study due to a myocardial infarction after 4 weeks of treatment, and 1 leflunomide-treated patient refused the second arthroscopy. Baseline synovial tissue biopsy samples from 1 patient in the leflunomide group and 1 patient in the methotrexate group were not assessable. The demographic characteristics of the 2 groups of RA patients were as follows: in the leflunomide group, 9 men and 7 women with a mean age of 60 years (range 35-77 years), a mean disease duration of 38', 'Patients. Thirty-nine patients were included in the study; paired synovial biopsy samples were available for 35 of them. One methotrexate-treated patient died during the study due to a myocardial infarction after 4 weeks of treatment, and 1 leflunomide-treated patient refused the second arthroscopy. Baseline synovial tissue biopsy samples from 1 patient in the leflunomide group and 1 patient in the methotrexate group were not assessable. The demographic characteristics of the 2 groups of RA patients were as follows: in the leflunomide group, 9 men and 7 women with a mean age of 60 years (range 35-77 years), a mean disease duration of 38', 'Paired synovial tissue sections were available in 35 patients (16 taking leflunomide, 19 taking methotrexate). Both drugs displayed equal clinical efficacy, with 8 leflunomide-treated patients (50%) and 10 methotrexate-treated patients (53%) fulfilling the American College of Rheumatology 20% response criteria.']}, 'the number of participants in the intervention groups who did experience the outcome of interest': {'extracted_data': ['10'], 'original_text_content': ['As shown in Figure 6, the calculated Kendall correlation coefficient revealed that changes in the expression of TNF‚ê£ correlated significantly with the clinical response, as defined by the ACR 20% response criteria (P œΩ 0.05). None of the other immunohistologic parameters showed a correlation with clinical response. Leflunomide-and methotrexate-treated patients who fulfilled the ACR 50% response criteria showed a more', 'The observation that beneficial changes in the MMP-1: TIMP-1 ratio were also found in those patients who did not fulfill the ACR 20% response criteria illustrates that inflammation and destruction may, in part, be separate processes.', 'Eight of the 16 patients treated with leflunomide (50%) and 10 of the 19 treated with methotrexate (53%) fulfilled the ACR 20% response criteria after 4 months of treatment.', 'The changes were more pronounced in patients who fulfilled the ACR 20% response criteria.']}, 'the number of participants in the intervention groups who did not experience the outcome of interest': {'extracted_data': [], 'original_text_content': ['Eight of the 16 patients treated with leflunomide (50%) and 10 of the 19 treated with methotrexate (53%) fulfilled the ACR 20% response criteria after 4 months of treatment.', 'Both drugs displayed equal clinical efficacy, with 8 leflunomide-treated patients (50%) and 10 methotrexate-treated patients (53%) fulfilling the American College of Rheumatology 20% response criteria.']}, 'the number of participants in the comparator groups who did experience the outcome of interest': {'extracted_data': ['8'], 'original_text_content': ['The trial included thirty-nine patients across two centers, and paired synovial tissue biopsy samples were collected at baseline and after four months of treatment.', 'Eight of the 16 patients treated with leflunomide (50%) and 10 of the 19 treated with methotrexate (53%) fulfilled the ACR 20% response criteria after 4 months of treatment.']}, 'the number of participants in the comparator groups who did not experience the outcome of interest': {'extracted_data': [], 'original_text_content': ['Responders displayed a reduction in expression of all markers, with the exception of IL-1‚ê§, which remained unchanged.', 'Eight of the 16 patients treated with leflunomide (50%) and 10 of the 19 treated with methotrexate (53%) fulfilled the ACR 20% response criteria after 4 months of treatment.', 'Nonresponders in the methotrexate group showed an increase in ICAM-1, VCAM-1, and TNF‚ê£ expression, whereas IL-1‚ê§ expression decreased slightly.', 'There was a decrease in VCAM-1 expression in the nonresponders and a more pronounced reduction in the responders.', 'In the leflunomide group, there was an increase in ICAM-1, TNF‚ê£, and IL-1‚ê§ expression in the nonresponders.', 'Responders to methotrexate displayed a reduction in the expression of all 4 markers.']}}, '2fb5f2ac': {'data_type': 'Dichotomous Data', 'the number of participants in the intervention groups': {'extracted_data': ['21'], 'original_text_content': ['Thirty-nine RA patients were included in the study (18 treated with leflunomide and 21 treated with methotrexate). Of these, a total of 34 patients had paired DEMRI scans (17 each in the leflunomide-and methotrexate-treated groups). One patient receiving methotrexate died of acute myocardial infarction (unrelated to study medication) before the 4-month data could be collected. The remaining methotrexate-and leflunomide-treated patients underwent both scan acquisitions, but due to technical difficulties, the baseline data for 4 patients were lost. The leflunomide-treated patients included 9 men and 9 women with a mean age of 60 years (range 36-77 years), a mean disease duration of 3.25 years (range 2 months-12 years), and a mean of 1.1 previous DMARD treatment regimens (range 0-3). The methotrexatetreated patients included 9 men and 12 women with a Clinical efficacy. Comparable changes from baseline in outcome measures of efficacy (Table 1) were observed in the leflunomide-and methotrexate-treated patients after 4 months of therapy. Nine of 18 patients (50%) in the leflunomide group and 10 of 21 patients (48%) in the methotrexate group met the ACR 20% response criteria. Overall, there was no statistically significant difference between treatment groups, although leflunomide-treated patients exhibited greater improvement in tender joint count, duration of morning stiffness, pain intensity (on a VAS), M-HAQ score, CRP level, and RF titer (Table 1). Methotrexate-treated patients showed greater improvement in ESR compared with baseline (Table 1). Dynamic MRI. A representative selection of 5 DEMRI sagittal T1-weighted sequence scans acquired post-Gd-DPTA injection is shown in Figure 2. SI curves were obtained over 321 seconds for sagittal slices through the knee and normalized with respect to baseline (precontrast). Figure 3 shows pooled histograms of the IRE for 17 scans pre-and posttreatment with either leflunomide or methotrexate. In the leflunomide-treated patients,', 'The table from the research paper titled \"Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging\" presents a comparison of various clinical parameters between patients treated with leflunomide (n=18) and those treated with methotrexate (n=21).', 'The methotrexate-treated patients included 9 men and 12 women with a Clinical efficacy.', 'Thirty-nine RA patients were included in the study (18 treated with leflunomide and 21 treated with methotrexate).', 'Thirty-nine RA patients were included in the study (18 treated with leflunomide and 21 treated with methotrexate). Of these, a total of 34 patients had paired DEMRI scans (17 each in the leflunomide-and methotrexate-treated groups). One patient receiving methotrexate died of acute myocardial infarction (unrelated to study medication) before the 4-month data could be collected. The remaining methotrexate-and leflunomide-treated patients underwent both scan acquisitions, but due to technical difficulties, the baseline data for 4 patients were lost. The leflunomide-treated patients included 9 men and 9 women with a mean age of 60 years (range 36-77 years), a mean disease duration of 3.25 years (range 2 months-12 years), and a mean of 1.1 previous DMARD treatment regimens (range 0-3). The methotrexatetreated patients included 9 men and 12 women with a Clinical efficacy. Comparable changes from baseline in outcome measures of efficacy (Table 1) were observed in the leflunomide-and methotrexate-treated patients after 4 months of therapy. Nine of 18 patients (50%) in the leflunomide group and 10 of 21 patients (48%) in the methotrexate group met the ACR 20% response criteria.']}, 'the number of participants in the comparator groups': {'extracted_data': ['18'], 'original_text_content': ['Thirty-nine RA patients were included in the study (18 treated with leflunomide and 21 treated with methotrexate). Of these, a total of 34 patients had paired DEMRI scans (17 each in the leflunomide-and methotrexate-treated groups). One patient receiving methotrexate died of acute myocardial infarction (unrelated to study medication) before the 4-month data could be collected. The remaining methotrexate-and leflunomide-treated patients underwent both scan acquisitions, but due to technical difficulties, the baseline data for 4 patients were lost. The leflunomide-treated patients included 9 men and 9 women with a mean age of 60 years (range 36-77 years), a mean disease duration of 3.25 years (range 2 months-12 years), and a mean of 1.1 previous DMARD treatment regimens (range 0-3). The methotrexatetreated patients included 9 men and 12 women with a Clinical efficacy. Comparable changes from baseline in outcome measures of efficacy (Table 1) were observed in the leflunomide-and methotrexate-treated patients after 4 months of therapy. Nine of 18 patients (50%) in the leflunomide group and 10 of 21 patients (48%) in the methotrexate group met the ACR 20% response criteria. Overall, there was no statistically significant difference between treatment groups, although leflunomide-treated patients exhibited greater improvement in tender joint count, duration of morning stiffness, pain intensity (on a VAS), M-HAQ score, CRP level, and RF titer (Table 1). Methotrexate-treated patients showed greater improvement in ESR compared with baseline (Table 1). Dynamic MRI. A representative selection of 5 DEMRI sagittal T1-weighted sequence scans acquired post-Gd-DPTA injection is shown in Figure 2. SI curves were obtained over 321 seconds for sagittal slices through the knee and normalized with respect to baseline (precontrast). Figure 3 shows pooled histograms of the IRE for 17 scans pre-and posttreatment with either leflunomide or methotrexate. In the leflunomide-treated patients,', 'The leflunomide-treated patients included 9 men and 9 women with a mean age of 60 years (range 36-77 years), a mean disease duration of 3.25 years (range 2 months-12 years), and a mean of 1.1 previous DMARD treatment regimens (range 0-3).', 'Thirty-nine RA patients were included in the study (18 treated with leflunomide and 21 treated with methotrexate).', 'During the 4-month treatment interval with 39 patients enrolled, both DMARDs showed generally comparable treatment effects in terms of the ACR 20% response criteria, representing a composite efficacy assessment.', 'Thirty-nine RA patients were included in the study (18 treated with leflunomide and 21 treated with methotrexate). Of these, a total of 34 patients had paired DEMRI scans (17 each in the leflunomide-and methotrexate-treated groups).']}, 'the number of participants in the intervention groups who did experience the outcome of interest': {'extracted_data': ['47.6%'], 'original_text_content': ['The table from the research paper titled \"Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging\" presents a comparison of various clinical parameters between patients treated with leflunomide (n=18) and those treated with methotrexate (n=21).', \"Statistical comparison of those meeting the ACR 20% improvement criteria (23) (ACR 20% responders) was by Fisher's exact test. Similarly, statistical analysis of the DEMRI parameters IRE and ME was based on mean changes from baseline to end point in the intent-to-treat population. Comparison between treatment groups was by the Mann-Whitney test. P values less than 0.05 were considered significant.\", 'ACR 20% responders (%)]: 50% of patients in the leflunomide group were responders, while 47.6% of methotrexate patients were responders, with a p-value of 1.000, indicating no significant difference between the two treatments.', 'During the 4-month treatment interval with 39 patients enrolled, both DMARDs showed generally comparable treatment effects in terms of the ACR 20% response criteria, representing a composite efficacy assessment.', \"Statistical comparison of those meeting the ACR 20% improvement criteria (23) (ACR 20% responders) was by Fisher's exact test.\", '11. **ACR 20% responders (%)**: 50% of patients in the leflunomide group were responders, while 47.6% of methotrexate patients were responders, with a p-value of 1.000, indicating no significant difference between the two treatments.', 'Nine of 18 patients (50%) in the leflunomide group and 10 of 21 patients (48%) in the methotrexate group met the ACR 20% response criteria.']}, 'the number of participants in the intervention groups who did not experience the outcome of interest': {'extracted_data': [], 'original_text_content': ['Thirty-nine RA patients were included in the study (18 treated with leflunomide and 21 treated with methotrexate). Of these, a total of 34 patients had paired DEMRI scans (17 each in the leflunomide-and methotrexate-treated groups). One patient receiving methotrexate died of acute myocardial infarction (unrelated to study medication) before the 4-month data could be collected. The remaining methotrexate-and leflunomide-treated patients underwent both scan acquisitions, but due to technical difficulties, the baseline data for 4 patients were lost. The leflunomide-treated patients included 9 men and 9 women with a mean age of 60 years (range 36-77 years), a mean disease duration of 3.25 years (range 2 months-12 years), and a mean of 1.1 previous DMARD treatment regimens (range 0-3). The methotrexatetreated patients included 9 men and 12 women with a Clinical efficacy. Comparable changes from baseline in outcome measures of efficacy (Table 1) were observed in the leflunomide-and methotrexate-treated patients after 4 months of therapy. Nine of 18 patients (50%) in the leflunomide group and 10 of 21 patients (48%) in the methotrexate group met the ACR 20% response criteria. Overall, there was no statistically significant difference between treatment groups, although leflunomide-treated patients exhibited greater improvement in tender joint count, duration of morning stiffness, pain intensity (on a VAS), M-HAQ score, CRP level, and RF titer (Table 1). Methotrexate-treated patients showed greater improvement in ESR compared with baseline (Table 1).', 'During the 4-month treatment interval with 39 patients enrolled, both DMARDs showed generally comparable treatment effects in terms of the ACR 20% response criteria, representing a composite efficacy assessment.', \"Statistical comparison of those meeting the ACR 20% improvement criteria (23) (ACR 20% responders) was by Fisher's exact test.\", '11. **ACR 20% responders (%)**: 50% of patients in the leflunomide group were responders, while 47.6% of methotrexate patients were responders, with a p-value of 1.000, indicating no significant difference between the two treatments.', 'Nine of 18 patients (50%) in the leflunomide group and 10 of 21 patients (48%) in the methotrexate group met the ACR 20% response criteria.']}, 'the number of participants in the comparator groups who did experience the outcome of interest': {'extracted_data': ['50%'], 'original_text_content': ['The table from the research paper titled \"Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging\" presents a comparison of various clinical parameters between patients treated with leflunomide (n=18) and those treated with methotrexate (n=21).', '11. **ACR 20% responders (%)**: 50% of patients in the leflunomide group were responders, while 47.6% of methotrexate patients were responders, with a p-value of 1.000, indicating no significant difference between the two treatments.', 'Nine of 18 patients (50%) in the leflunomide group and 10 of 21 patients (48%) in the methotrexate group met the ACR 20% response criteria.']}, 'the number of participants in the comparator groups who did not experience the outcome of interest': {'extracted_data': [], 'original_text_content': ['Thirty-nine RA patients were included in the study (18 treated with leflunomide and 21 treated with methotrexate).', '11. **ACR 20% responders (%)**: 50% of patients in the leflunomide group were responders, while 47.6% of methotrexate patients were responders, with a p-value of 1.000, indicating no significant difference between the two treatments.', 'Nine of 18 patients (50%) in the leflunomide group and 10 of 21 patients (48%) in the methotrexate group met the ACR 20% response criteria.']}}, '838a2e2f': {'data_type': 'Dichotomous Data', 'the number of participants in the intervention groups': {'extracted_data': ['42'], 'original_text_content': ['The clinical trial comparing the efficacy and safety of Leflunomide (LFN) 100 mg/week to Methotrexate (MTX) 10 mg/week in patients with active Rheumatoid Arthritis (RA) included a total of 85 patients who were randomized into two groups: 43 patients received Leflunomide and 42 received Methotrexate.', 'Of the 90 patients evaluated for study entry, 5 were excluded, and the 85 remaining were randomized into 2 groups as follows: a group of 43 patients were assigned to LFN and 42 to MTX (Fig. 1).']}, 'the number of participants in the comparator groups': {'extracted_data': ['43'], 'original_text_content': [\"The provided HTML table presents data comparing the incidence of various adverse events between two groups of Rheumatoid Arthritis patients undergoing different treatments, specifically Leflunomide (LFN) 100 mg/week and Methotrexate (MTX) 10 mg/week. The table's column headers indicate that there were 43 patients in the LFN group and 42 in the MTX group.\", 'The clinical trial comparing the efficacy and safety of Leflunomide (LFN) 100 mg/week to Methotrexate (MTX) 10 mg/week in patients with active Rheumatoid Arthritis (RA) included a total of 85 patients who were randomized into two groups: 43 patients received Leflunomide and 42 received Methotrexate.', 'Of the 90 patients evaluated for study entry, 5 were excluded, and the 85 remaining were randomized into 2 groups as follows: a group of 43 patients were assigned to LFN and 42 to MTX (Fig. 1).']}, 'the number of participants in the intervention groups who did experience the outcome of interest': {'extracted_data': ['25'], 'original_text_content': ['For the MTX group the results showed that 30 patients (83%) achieved ACR 20 at week 24 and 25 (78.1%) at week 52;', 'For the MTX group the results showed that 30 patients (83%) achieved ACR 20 at week 24 and 25 (78.1%) at week 52; comparing the two groups, there was no statistically significant difference (Fig. 2).', 'Of patients who completed the study in the LFN group, 28 achieved an ACR 20 response (90.3%) at week 52 (Fig. 2); however, applying the calculation of patients intended to treat (ITT), the ACR 20 response was 67.4%. Two patients were eliminated from the LFN group for not achieving ACR 20 improvement, compared to MTX where 4 cases did not achieve it.']}, 'the number of participants in the intervention groups who did not experience the outcome of interest': {'extracted_data': [], 'original_text_content': ['The criteria for discontinuation of patients in the study were applied to all those who did not achieve ACR 20 improvement at week 16, or if the patient had serious adverse events (SAE), which would require unblinding the drug safety status.', 'Discontinuation due to lack of efficacy was found in 2 patients in the LFN group (5.2%) and in 4 cases with MTX (12.1%) (Fig. 1).', 'For the MTX group the results showed that 30 patients (83%) achieved ACR 20 at week 24 and 25 (78.1%) at week 52; comparing the two groups, there was no statistically significant difference (Fig. 2).', 'The ACR improvement criteria were assessed at weeks 8, 24, and 52. In patients assigned to LFN, 28 (80%) achieved ACR 20 at week 24 and in 29 cases (93.5%) at week 52. For the MTX group the results showed that 30 patients (83%) achieved ACR 20 at week 24 and 25 (78.1%) at week 52; comparing the two groups, there was no statistically significant difference (Fig. 2).', 'Of patients who completed the study in the LFN group, 28 achieved an ACR 20 response (90.3%) at week 52 (Fig. 2); however, applying the calculation of patients intended to treat (ITT), the ACR 20 response was 67.4%. Two patients were eliminated from the LFN group for not achieving ACR 20 improvement, compared to MTX where 4 cases did not achieve it.', 'The ACR improvement criteria were assessed at weeks 8, 24, and 52. In patients assigned to LFN, 28 (80%) achieved ACR 20 at week 24 and in 29 cases (93.5%) at week 52. For the MTX group the results showed that 30 patients (83%) achieved ACR 20 at week 24 and 25 (78.1%) at week 52;', 'Of the 90 patients evaluated for study entry, 5 were excluded, and the 85 remaining were randomized into 2 groups as follows: a group of 43 patients were assigned to LFN and 42 to MTX (Fig. 1).']}, 'the number of participants in the comparator groups who did experience the outcome of interest': {'extracted_data': ['29'], 'original_text_content': ['In patients assigned to LFN, 28 (80%) achieved ACR 20 at week 24 and in 29 cases (93.5%) at week 52.']}, 'the number of participants in the comparator groups who did not experience the outcome of interest': {'extracted_data': [], 'original_text_content': ['Of the 90 patients evaluated for study entry, 5 were excluded, and the 85 remaining were randomized into 2 groups as follows: a group of 43 patients were assigned to LFN and 42 to MTX (Fig. 1). Both groups of patients were assessed at least once during follow up from the baseline visit. The demographics and disease characteristics were similar for both groups (Table 1). Three patients were treated with DMARDs prior to enrollment, 2 for the LFN group. One of them who received LFN 20 mg/day and hydroxychloroquine for 2 months discontinued treatment for 7 months before being randomized to the LFN group. A second patient, with an irregular treatment, took MTX for a month, 3 months after being randomized to the LFN group. Finally, in a patient receiving conventional LFN, diffuse alopecia developed after 2¬Ω months and treatment was suspended; the patient was sent to our hospital and included in pre-randomization, after no treatment was given for 3 months, to the MTX group. Sixty-three patients completed 52 weeks of treatment, 31 in the LFN (72%) and 32 in the MTX group (74.4%). Early discontinuation of patients at week 16 occurred more often in the LFN than in the MTX group (19.4 vs 5%), respectively. At the end of the study, the total of patients who left were 21, either by loss to follow up or adverse events. Twelve cases occurred (27.9%) in the LFN and 10 patients (23.8%) in the Improvement, % Fig. 2. Percentage of patients reaching the ACR 20 response criteria at 24 and 52 weeks. There were no statistically significant differences between groups. MTX group. Discontinuation due to lack of efficacy was found in 2 patients in the LFN group (5.2%) and in 4 cases with MTX (12.1%) (Fig. 1). The ACR improvement criteria were assessed at weeks 8, 24, and 52. In patients assigned to LFN, 28 (80%) achieved ACR 20 at week 24 and in 29 cases (93.5%) at week 52. For the MTX group the results showed that 30 patients (83%) achieved ACR 20 at week 24 and 25 (78.1%) at week 52;', 'In patients assigned to LFN, 28 (80%) achieved ACR 20 at week 24 and in 29 cases (93.5%) at week 52.']}}}, 'No of participants': {'Methotrexate (MTX)': '97/270 (35.93%)', 'Leflunomide (LEF)': '104/266 (39.10%)'}, 'Effect': {'Relative Effect (95% CI)': 'RR 0.9052 [0.7466; 1.0975] ', 'Absolute Effect (95% CI)': '36.6 fewer per 1000 (from 113.5 fewer to 40.3 more)'}, 'Risk of bias': {'result': 'SERIOUS', 'rationales': \"The overall risk of bias in the body of evidence is assessed as 'serious' (-1) based on the following considerations: 1) Allocation concealment was generally adequate across studies, with most trials reporting proper randomization and blinding procedures. However, one study (uid:17e8ec8b) lacked explicit details on allocation concealment, introducing some uncertainty. 2) Blinding was well-maintained across all studies, with no evidence of unblinding reported. 3) Incomplete accounting of patients and outcome events was noted in several studies, particularly due to loss to follow-up and exclusions from analyses, which could introduce bias. For example, studies uid:471ba650, uid:17e8ec8b, and uid:838a2e2f had attrition rates ranging from 9% to 25%, potentially affecting the validity of results. 4) Other limitations included small sample sizes in some studies (e.g., uid:17e8ec8b with 15 patients) and short follow-up durations, which may limit the generalizability and robustness of findings. Despite these limitations, the majority of studies were well-conducted with balanced baseline characteristics and appropriate statistical methods, supporting the reliability of the evidence to a reasonable extent.\"}, 'Inconsistency': {'result': 'NOT_SERIOUS'}, 'Indirectness': {'result': 'NOT_SERIOUS'}, 'Imprecision': {'result': 'SERIOUS', 'rationales': 'The confidence interval crosses the line of no effect (RR\\u202f=\\u202f1) and includes both potential benefit and no effect, indicating serious imprecision.'}, 'Certainty': 'LOW'}}}, {'outcome_uid': '3f9443a5', 'clinical_question': 'Should Methotrexate or leflunomide be the first choice for initial treatment of rheumatoid arthritis?', 'population': 'Treatment-na√Øve patients with rheumatoid arthritis', 'intervention': 'Methotrexate (MTX)', 'comparator': 'Leflunomide (LEF)', 'outcome': 'Serious adverse events', 'importance': 'IMPORTANT', 'related_paper_list': ['7e71e218'], 'assessment_results': {'GRADE': {'Study design': 'RANDOMIZED_CONTROLLED_TRIAL', 'Raw data from evidence': {'7e71e218': {'data_type': 'Dichotomous Data', 'the number of participants in the intervention groups': {'extracted_data': ['111'], 'original_text_content': ['In this study, the efficacy and safety of leflunomide (LEF) and methotrexate (MTX) for treating rheumatoid arthritis in low socioeconomic patients were compared over a duration of one year. The clinical trial involved two groups: 91 patients received leflunomide (LEF) and 89 patients received methotrexate (MTX).', 'A total of 368 subjects were enrolled in this study. Of these, 128 subjects were withdrawn in the screening phase. Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate.', 'A total of 180 subjects (91 leflunomide and 89 methotrexate) completed the 52-week treatment phase.']}, 'the number of participants in the comparator groups': {'extracted_data': ['129'], 'original_text_content': ['In this study, the efficacy and safety of leflunomide (LEF) and methotrexate (MTX) for treating rheumatoid arthritis in low socioeconomic patients were compared over a duration of one year. The clinical trial involved two groups: 91 patients received leflunomide (LEF) and 89 patients received methotrexate (MTX).', 'A total of 368 subjects were enrolled in this study. Of these, 128 subjects were withdrawn in the screening phase. Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate.', 'A total of 180 subjects (91 leflunomide and 89 methotrexate) completed the 52-week treatment phase.']}, 'the number of participants in the intervention groups who did experience the outcome of interest': {'extracted_data': ['15% (withdrawal due to adverse events)'], 'original_text_content': ['In both treatment groups, the most common reason for withdrawal during the treatment was adverse events. This accounted for 19% of the withdrawals in the leflunomide group and 15% in the methotrexate group.', 'A total of 368 subjects were enrolled in this study. Of these, 128 subjects were withdrawn in the screening phase. Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate. The demographic characteristics of the treatment groups are shown in Table 1. In both treatment groups, the most common reason for withdrawal during the treatment was adverse events. This accounted for 19% of the withdrawals in the leflunomide group and 15% in the methotrexate group.', 'The most notable difference in the adverse event profiles of the two treatment groups was the high incidence of abnormal plasma liver enzyme levels in subjects receiving methotrexate. Withdrawal rates for all adverse events were comparable in both treatment groups, with the exception of those for diarrhea, which was more common in leflunomide-treated subjects, and nausea and abnormal plasma liver enzyme levels, which were more common in methotrexate-treated subjects.', 'A total of 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate.', 'The most common adverse events resulting in withdrawal during leflunomide treatment were elevated plasma liver enzyme levels, nausea and diarrhea. A similar pattern was seen in the subjects treated with methotrexate, but the number of withdrawals due to elevations of plasma enzyme levels was twice as high as that seen with leflunomide. The overall incidence of treatment-related elevations of plasma liver enzyme levels in the trial was threefold higher with methotrexate than with leflunomide.', 'A total of 240 subjects were randomized and treated, 129 received leflunomide and 111 received methotrexate.', 'A total of 368 subjects were enrolled in this study. Of these, 128 subjects were withdrawn in the screening phase. Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate.', 'Withdrawal rates for all adverse events were comparable in both treatment groups, with the exception of those for diarrhea, which was more common in leflunomide-treated subjects, and nausea and abnormal plasma liver enzyme levels, which were more common in methotrexate-treated subjects.']}, 'the number of participants in the intervention groups who did not experience the outcome of interest': {'extracted_data': [], 'original_text_content': ['In both treatment groups, the most common reason for withdrawal during the treatment was adverse events. This accounted for 19% of the withdrawals in the leflunomide group and 15% in the methotrexate group.', 'A total of 180 subjects (91 leflunomide and 89 methotrexate) completed the 52-week treatment phase.', 'The most common treatment-related adverse events in subjects receiving leflunomide were diarrhea and nausea. The frequencies of nausea and diarrhea were highest during', 'The most common adverse events resulting in withdrawal during leflunomide treatment were elevated plasma liver enzyme levels, nausea and diarrhea. A similar pattern was seen in the subjects treated with methotrexate, but the number of withdrawals due to elevations of plasma enzyme levels was twice as high as that seen with leflunomide. The overall incidence of treatment-related elevations of plasma liver enzyme levels in the trial was threefold higher with methotrexate than with leflunomide.', 'A total of 368 subjects were enrolled in this study. Of these, 128 subjects were withdrawn in the screening phase. Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate. The demographic characteristics of the treatment groups are shown in Table 1. In both treatment groups, the most common reason for withdrawal during the treatment was adverse events. This accounted for 19% of the withdrawals in the leflunomide group and 15% in the methotrexate group. Lack of efficacy was the next most common reason for withdrawal, and was cited as the reason for 7% of the withdrawals in the leflunomide-treated and 3% of the withdrawals in methotrexate-treated subjects. A total of 180 subjects (91 leflunomide and 89 methotrexate) completed the 52-week treatment phase.', 'A total of 240 subjects were randomized and treated, 129 received leflunomide and 111 received methotrexate.', 'A total of 368 subjects were enrolled in this study. Of these, 128 subjects were withdrawn in the screening phase. Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate.', 'The most common reason for withdrawal during the treatment was adverse events. This accounted for 19% of the withdrawals in the leflunomide group and 15% in the methotrexate group.', 'The most common treatment-related adverse events in subjects receiving leflunomide were diarrhea and nausea. The frequencies of nausea and diarrhea were highest during the first two weeks of treatment with leflunomide or methotrexate, and declined thereafter (Table 4). The most notable difference in the adverse event profiles of the two treatment groups was the high incidence of abnormal plasma liver enzyme levels in subjects receiving methotrexate. Withdrawal rates for all adverse events were comparable in both treatment groups, with the exception of those for diarrhea, which was more common in leflunomide-treated subjects, and nausea and abnormal plasma liver enzyme levels, which were more common in methotrexate-treated subjects.']}, 'the number of participants in the comparator groups who did experience the outcome of interest': {'extracted_data': ['19% of 129 leflunomide-treated subjects experienced adverse events leading to withdrawal, but the number of serious adverse events is not specified.'], 'original_text_content': ['In both treatment groups, the most common reason for withdrawal during the treatment was adverse events. This accounted for 19% of the withdrawals in the leflunomide group and 15% in the methotrexate group.', 'A total of 368 subjects were enrolled in this study. Of these, 128 subjects were withdrawn in the screening phase. Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate. The demographic characteristics of the treatment groups are shown in Table 1. In both treatment groups, the most common reason for withdrawal during the treatment was adverse events. This accounted for 19% of the withdrawals in the leflunomide group and 15% in the methotrexate group.', 'The most common adverse events resulting in withdrawal during leflunomide treatment were elevated plasma liver enzyme levels, nausea and diarrhea. A similar pattern was seen in the subjects treated with methotrexate, but the number of withdrawals due to elevations of plasma enzyme levels was twice as high as that seen with leflunomide. The overall incidence of treatment-related elevations of plasma liver enzyme levels in the trial was threefold higher with methotrexate than with leflunomide.', 'A total of 368 subjects were enrolled in this study. Of these, 128 subjects were withdrawn in the screening phase. Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate.', 'The most common treatment-related adverse events in subjects receiving leflunomide were diarrhea and nausea. The frequencies of nausea and diarrhea were highest during the first two weeks of treatment with leflunomide or methotrexate, and declined thereafter (Table 4). The most notable difference in the adverse event profiles of the two treatment groups was the high incidence of abnormal plasma liver enzyme levels in subjects receiving methotrexate. Withdrawal rates for all adverse events were comparable in both treatment groups, with the exception of those for diarrhea, which was more common in leflunomide-treated subjects, and nausea and abnormal plasma liver enzyme levels, which were more common in methotrexate-treated subjects.']}, 'the number of participants in the comparator groups who did not experience the outcome of interest': {'extracted_data': [], 'original_text_content': ['In both treatment groups, the most common reason for withdrawal during the treatment was adverse events. This accounted for 19% of the withdrawals in the leflunomide group and 15% in the methotrexate group.', 'A total of 180 subjects (91 leflunomide and 89 methotrexate) completed the 52-week treatment phase.', 'A total of 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate.', 'A total of 368 subjects were enrolled in this study. Of these, 128 subjects were withdrawn in the screening phase. Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate. The demographic characteristics of the treatment groups are shown in Table 1. In both treatment groups, the most common reason for withdrawal during the treatment was adverse events. This accounted for 19% of the withdrawals in the leflunomide group and 15% in the methotrexate group. Lack of efficacy was the next most common reason for withdrawal, and was cited as the reason for 7% of the withdrawals in the leflunomide-treated and 3% of the withdrawals in methotrexate-treated subjects. A total of 180 subjects (91 leflunomide and 89 methotrexate) completed the 52-week treatment phase.', 'A total of 368 subjects were enrolled in this study. Of these, 128 subjects were withdrawn in the screening phase. Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate.', 'The most common treatment-related adverse events in subjects receiving leflunomide were diarrhea and nausea. The frequencies of nausea and diarrhea were highest during the first two weeks of treatment with leflunomide or methotrexate, and declined thereafter (Table 4). The most notable difference in the adverse event profiles of the two treatment groups was the high incidence of abnormal plasma liver enzyme levels in subjects receiving methotrexate. Withdrawal rates for all adverse events were comparable in both treatment groups, with the exception of those for diarrhea, which was more common in leflunomide-treated subjects, and nausea and abnormal plasma liver enzyme levels, which were more common in methotrexate-treated subjects.']}}}, 'No of participants': {'Methotrexate (MTX)': '17/111 (15.32%)', 'Leflunomide (LEF)': '25/129 (19.38%)'}, 'Effect': {'Relative Effect (95% CI)': 'RR 0.7903 [0.4507; 1.3855] ', 'Absolute Effect (95% CI)': '40.6 fewer per 1000 (from 136.3 fewer to 55 more)'}, 'Risk of bias': {'result': 'SERIOUS', 'rationales': \"The study has some limitations that warrant a 'serious' rating for risk of bias. The primary concern is the unclear allocation concealment, which raises the potential for selection bias. However, the study was double-blinded, reducing performance and detection bias, and there was no evidence of incomplete accounting of patients or outcome events. The sample size was adequate (240 randomized patients), and the study was powered to detect differences in efficacy and safety. The high withdrawal rate (~25%) due to adverse events is a concern but was balanced between groups and well-documented. Given these factors, the overall risk of bias is considered moderate, leading to a downgrade of one level.\"}, 'Inconsistency': {'result': 'NOT_SERIOUS'}, 'Indirectness': {'result': 'NOT_SERIOUS'}, 'Imprecision': {'result': 'SERIOUS', 'rationales': 'The confidence interval is wide and crosses the line of no effect, encompassing both potential benefit and harm, and the total number of events (n\\u202f=\\u202f42) is small, indicating serious imprecision.'}, 'Certainty': 'LOW'}}}, {'outcome_uid': '067abd99', 'clinical_question': 'Should Methotrexate or leflunomide be the first choice for initial treatment of rheumatoid arthritis?', 'population': 'Treatment-na√Øve patients with rheumatoid arthritis', 'intervention': 'Methotrexate (MTX)', 'comparator': 'Leflunomide (LEF)', 'outcome': 'Withdrawal due to lack of efficacy', 'importance': 'IMPORTANT', 'related_paper_list': ['7e71e218'], 'assessment_results': {'GRADE': {'Study design': 'RANDOMIZED_CONTROLLED_TRIAL', 'Raw data from evidence': {'7e71e218': {'data_type': 'Dichotomous Data', 'the number of participants in the intervention groups': {'extracted_data': ['111'], 'original_text_content': ['A total of 368 subjects were enrolled in this study. Of these, 128 subjects were withdrawn in the screening phase. Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate.', 'A total of 180 subjects (91 leflunomide and 89 methotrexate) completed the 52-week treatment phase.']}, 'the number of participants in the comparator groups': {'extracted_data': ['129'], 'original_text_content': ['A total of 368 subjects were enrolled in this study. Of these, 128 subjects were withdrawn in the screening phase. Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate.', 'A total of 180 subjects (91 leflunomide and 89 methotrexate) completed the 52-week treatment phase.']}, 'the number of participants in the intervention groups who did experience the outcome of interest': {'extracted_data': ['3%'], 'original_text_content': ['A total of 368 subjects were enrolled in this study. Of these, 128 subjects were withdrawn in the screening phase. Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate. The demographic characteristics of the treatment groups are shown in Table 1. In both treatment groups, the most common reason for withdrawal during the treatment was adverse events. This accounted for 19% of the withdrawals in the leflunomide group and 15% in the methotrexate group. Lack of efficacy was the next most common reason for withdrawal, and was cited as the reason for 7% of the withdrawals in the leflunomide-treated and 3% of the withdrawals in methotrexate-treated subjects. A total of 180 subjects (91 leflunomide and 89 methotrexate) completed the 52-week treatment phase.', 'Lack of efficacy was the next most common reason for withdrawal, and was cited as the reason for 7% of the withdrawals in the leflunomide-treated and 3% of the withdrawals in methotrexate-treated subjects.', 'Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate.']}, 'the number of participants in the intervention groups who did not experience the outcome of interest': {'extracted_data': [], 'original_text_content': ['A total of 368 subjects were enrolled in this study. Of these, 128 subjects were withdrawn in the screening phase. Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate. The demographic characteristics of the treatment groups are shown in Table 1. In both treatment groups, the most common reason for withdrawal during the treatment was adverse events. This accounted for 19% of the withdrawals in the leflunomide group and 15% in the methotrexate group. Lack of efficacy was the next most common reason for withdrawal, and was cited as the reason for 7% of the withdrawals in the leflunomide-treated and 3% of the withdrawals in methotrexate-treated subjects. A total of 180 subjects (91 leflunomide and 89 methotrexate) completed the 52-week treatment phase.', 'A total of 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate.', 'Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate.', 'Lack of efficacy was the next most common reason for withdrawal, and was cited as the reason for 7% of the withdrawals in the leflunomide-treated and 3% of the withdrawals in methotrexate-treated subjects.']}, 'the number of participants in the comparator groups who did experience the outcome of interest': {'extracted_data': ['7%'], 'original_text_content': ['A total of 368 subjects were enrolled in this study. Of these, 128 subjects were withdrawn in the screening phase. Of the 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate. The demographic characteristics of the treatment groups are shown in Table 1. In both treatment groups, the most common reason for withdrawal during the treatment was adverse events. This accounted for 19% of the withdrawals in the leflunomide group and 15% in the methotrexate group. Lack of efficacy was the next most common reason for withdrawal, and was cited as the reason for 7% of the withdrawals in the leflunomide-treated and 3% of the withdrawals in methotrexate-treated subjects. A total of 180 subjects (91 leflunomide and 89 methotrexate) completed the 52-week treatment phase.', 'Lack of efficacy was the next most common reason for withdrawal, and was cited as the reason for 7% of the withdrawals in the leflunomide-treated and 3% of the withdrawals in methotrexate-treated subjects.', 'A total of 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate.', 'In both treatment groups, the most common reason for withdrawal during the treatment was adverse events. This accounted for 19% of the withdrawals in the leflunomide group and 15% in the methotrexate group. Lack of efficacy was the next most common reason for withdrawal, and was cited as the reason for 7% of the withdrawals in the leflunomide-treated and 3% of the withdrawals in methotrexate-treated subjects.']}, 'the number of participants in the comparator groups who did not experience the outcome of interest': {'extracted_data': [], 'original_text_content': ['A total of 240 subjects randomized and treated, 129 received leflunomide and 111 received methotrexate.', 'Lack of efficacy was the next most common reason for withdrawal, and was cited as the reason for 7% of the withdrawals in the leflunomide-treated and 3% of the withdrawals in methotrexate-treated subjects.']}}}, 'No of participants': {'Methotrexate (MTX)': '3/111 (2.70%)', 'Leflunomide (LEF)': '9/129 (6.98%)'}, 'Effect': {'Relative Effect (95% CI)': 'RR 0.3874 [0.1075; 1.3958] ', 'Absolute Effect (95% CI)': '42.7 fewer per 1000 (from 96.1 fewer to 10.6 more)'}, 'Risk of bias': {'result': 'SERIOUS', 'rationales': 'The study has some limitations that warrant downgrading the certainty of evidence by one level (serious risk of bias). The primary concern is the unclear allocation concealment, which introduces uncertainty about potential selection bias. While the study was double-blinded and had clear reporting of patient flow and outcome events, the lack of mandated folate supplementation in the methotrexate group and differential dropout rates (higher in the leflunomide group) could influence the outcome of withdrawal due to lack of efficacy. These factors collectively suggest a serious but not very serious risk of bias in the overall evidence.'}, 'Inconsistency': {'result': 'NOT_SERIOUS'}, 'Indirectness': {'result': 'NOT_SERIOUS'}, 'Imprecision': {'result': 'SERIOUS', 'rationales': 'The confidence interval is very wide and crosses the line of no effect, encompassing both substantial benefit and harm. The total number of events (n\\u202f=\\u202f12) is extremely small, indicating very serious imprecision.'}, 'Certainty': 'LOW'}}}, {'outcome_uid': '3949f261', 'clinical_question': 'Should Methotrexate or leflunomide be the first choice for initial treatment of rheumatoid arthritis?', 'population': 'Treatment-na√Øve patients with rheumatoid arthritis', 'intervention': 'Methotrexate (MTX)', 'comparator': 'Leflunomide (LEF)', 'outcome': 'Disease activity (assessed with: DAS (Lower values ‚Üí benefit))', 'importance': 'CRITICAL', 'related_paper_list': ['903a6edb'], 'assessment_results': {'GRADE': {'Study design': 'RANDOMIZED_CONTROLLED_TRIAL', 'Raw data from evidence': {'903a6edb': {'data_type': 'Continuous Data', 'the number of participants in the intervention groups': {'extracted_data': ['49'], 'original_text_content': ['A total of 102 (53 leflunomide and 49 methotrexate treated) patients were selected out of 999 RA patients who participated in a prospective, double blind, randomized clinical trial comparing leflunomide and methotrexate.', 'Sample Size: The study included 53 patients treated with leflunomide and 49 with methotrexate.', 'The study included 53 patients treated with leflunomide and 49 with methotrexate.']}, 'the number of participants in the comparator groups': {'extracted_data': ['53'], 'original_text_content': ['A total of 102 (53 leflunomide and 49 methotrexate treated) patients were selected out of 999 RA patients who participated in a prospective, double blind, randomized clinical trial comparing leflunomide and methotrexate.', 'The study included 53 patients treated with leflunomide and 49 with methotrexate.']}, 'the number of participants in the intervention groups who did experience the outcome of interest': {'extracted_data': ['Mean 4.4 SD 1.4'], 'original_text_content': ['Patients had active disease as shown by high Disease Activity Score (DAS, mean of 6.9 and 7.0 for methotrexate and leflunomide patients respectively), which was reduced over the study period (4.2 and 5.2 respectively, P < 0.001).', 'Methotrexate patients saw a DAS reduction from 7.04 at baseline to 5.24 at 4 months and 4.44 at 1 year.', 'The study included 53 patients treated with leflunomide and 49 with methotrexate.', 'Demographic and clinical data are depicted in Table 1. All patients had very active disease at baseline, as measured by the disease activity score (DAS) of 6.9 ¬± 1 (mean ¬± sd) for the leflunomide patients and 7.0 ¬± 0.9 for the methotrexate patients, with a significant reduction after 4 months, and after 1 year in both leflunomide and methotrexate treated patients (Table 1).', 'In line with previous results, the CRP levels were significantly lower after 1 year of treatment in methotrexate group as compared to leflunomide treatment group (P = 0.014).']}, 'the number of participants in the intervention groups who did not experience the outcome of interest': {'extracted_data': [], 'original_text_content': ['Patients had active disease as shown by high Disease Activity Score (DAS, mean of 6.9 and 7.0 for methotrexate and leflunomide patients respectively), which was reduced over the study period (4.2 and 5.2 respectively, P < 0.001).', 'Leflunomide patients had a DAS of 6.9 at baseline, reducing to 5.24 at 4 months, and further lowering at 1 year. Methotrexate patients saw a DAS reduction from 7.04 at baseline to 5.24 at 4 months and 4.44 at 1 year.', 'The study included 53 patients treated with leflunomide and 49 with methotrexate.', 'Methotrexate patients saw a DAS reduction from 7.04 at baseline to 5.24 at 4 months and 4.44 at 1 year.', 'All patients had very active disease at baseline, as measured by the disease activity score (DAS) of 6.9 ¬± 1 (mean ¬± sd) for the leflunomide patients and 7.0 ¬± 0.9 for the methotrexate patients, with a significant reduction after 4 months, and after 1 year in both leflunomide and methotrexate treated patients (Table 1).', 'The C-reactive protein (CRP) levels were significantly reduced in both leflunomide and methotrexate patients (Table 1). In line with previous results, the CRP levels were significantly lower after 1 year of treatment in methotrexate group as compared to leflunomide treatment group (P = 0.014).', 'A total of 102 (53 leflunomide and 49 methotrexate treated) patients were selected out of 999 RA patients who participated in a prospective, double blind, randomized clinical trial comparing leflunomide and methotrexate.', 'Significant reduction over time was noted in both treatment groups. Leflunomide patients had a DAS of 6.9 at baseline, reducing to 5.24 at 4 months, and further lowering at 1 year. Methotrexate patients saw a DAS reduction from 7.04 at baseline to 5.24 at 4 months and 4.44 at 1 year.']}, 'the number of participants in the comparator groups who did experience the outcome of interest': {'extracted_data': ['Mean 5.2 SD 1.5'], 'original_text_content': ['In leflunomide treated patients a significant reduction of MMP activity levels was observed as early as at 4 month time point persisting thereafter, whereas in methotrexate treated patients the reduction was found at 1 year.', 'The study included 53 patients treated with leflunomide and 49 with methotrexate.', 'All patients had very active disease at baseline, as measured by the disease activity score (DAS) of 6.9 ¬± 1 (mean ¬± sd) for the leflunomide patients and 7.0 ¬± 0.9 for the methotrexate patients, with a significant reduction after 4 months, and after 1 year in both leflunomide and methotrexate treated patients (Table 1).', 'A total of 102 (53 leflunomide and 49 methotrexate treated) patients were selected out of 999 RA patients who participated in a prospective, double blind, randomized clinical trial comparing leflunomide and methotrexate.', 'Significant reduction over time was noted in both treatment groups.', 'Leflunomide patients had a DAS of 6.9 at baseline, reducing to 5.24 at 4 months, and further lowering at 1 year (though recorded as `6941` implies a typo; potentially `6.94 ¬± 1`). Methotrexate patients saw a DAS reduction from 7.04 at baseline to 5.24 at 4 months and 4.44 at 1 year.']}, 'the number of participants in the comparator groups who did not experience the outcome of interest': {'extracted_data': [], 'original_text_content': ['Patients had active disease as shown by high Disease Activity Score (DAS, mean of 6.9 and 7.0 for methotrexate and leflunomide patients respectively), which was reduced over the study period (4.2 and 5.2 respectively, P < 0.001).', 'In leflunomide treated patients a significant reduction of MMP activity levels was observed as early as at 4 month time point persisting thereafter, whereas in methotrexate treated patients the reduction was found at 1 year.', 'The study included 53 patients treated with leflunomide and 49 with methotrexate.', 'The statistical significance is evident across time points for leflunomide (p<0.001), while methotrexate showed significant changes only after 1 year (p = 0.007).', 'A total of 102 (53 leflunomide and 49 methotrexate treated) patients were selected out of 999 RA patients who participated in a prospective, double blind, randomized clinical trial comparing leflunomide and methotrexate.', 'Significant reduction over time was noted in both treatment groups.', 'In line with previous results, the CRP levels were significantly lower after 1 year of treatment in methotrexate group as compared to leflunomide treatment group (P = 0.014).', 'Leflunomide patients had a DAS of 6.9 at baseline, reducing to 5.24 at 4 months, and further lowering at 1 year (though recorded as `6941` implies a typo; potentially `6.94 ¬± 1`). Methotrexate patients saw a DAS reduction from 7.04 at baseline to 5.24 at 4 months and 4.44 at 1 year.']}}}, 'No of participants': {'Methotrexate (MTX)': '49', 'Leflunomide (LEF)': '53'}, 'Effect': {'Relative Effect (95% CI)': '-', 'Absolute Effect (95% CI)': 'MD 0.83 lower (1.09 lower to 0.57 lower) '}, 'Risk of bias': {'result': 'SERIOUS', 'rationales': \"The study demonstrates robust outcomes with a well-defined sample size and clear longitudinal data, including significant reductions in DAS, CRP levels, and Œ±2M/MMP activity. However, the risk of bias is considered serious due to the lack of explicit description of allocation concealment, which raises concerns about potential selection bias. While the trial maintained adequate blinding and did not have incomplete accounting of patients and outcome events, the absence of details on allocation concealment methods weakens the study's internal validity. Given the GRADE framework's emphasis on conservative judgment and the substantial contribution of this study to the evidence base, the risk of bias warrants downgrading by one level.\"}, 'Inconsistency': {'result': 'NOT_SERIOUS'}, 'Indirectness': {'result': 'NOT_SERIOUS'}, 'Imprecision': {'result': 'SERIOUS', 'rationales': 'Downgraded one level for imprecision due to the small total sample size (n=102), which did not meet the optimal information size (OIS) criteria, although the confidence interval did not cross the line of no effect.'}, 'Certainty': 'LOW'}}}], 'overall_certainty': 'LOW'}}, 'supplementary_information': ''}\n"
     ]
    }
   ],
   "source": [
    "quicker_data = QuickerData(disease=disease,pico_idx=pico_idx)\n",
    "quicker = Quicker(\n",
    "    config_path=YOUR_CONFIG_PATH,\n",
    "    question_deconstruction_database_path=YOUR_QUESTION_DECOMPOSTITION_PATH,\n",
    "    literature_search_database_path=YOUR_LITERATURE_SEARCH_PATH,\n",
    "    study_selection_database_path=YOUR_STUDY_SELECTION_PATH,\n",
    "    evidence_assessment_database_path=YOUR_EVIDENCE_ASSESSMENT_PATH,\n",
    "    quicker_data=quicker_data,\n",
    "    paper_library_base=YOUR_PAPER_LIBRARY_PATH,\n",
    ")\n",
    "\n",
    "\n",
    "question_deconstruction_datapath = os.path.join(\n",
    "    quicker.question_deconstruction_database_path, 'PICO_Information.json'\n",
    ")\n",
    "question_deconstruction_data = pd.read_json(\n",
    "    question_deconstruction_datapath, dtype={'Index': str}\n",
    ")\n",
    "question_deconstruction_data = question_deconstruction_data[\n",
    "    question_deconstruction_data['Index'] == pico_idx\n",
    "]\n",
    "original_qd_dict = question_deconstruction_data.to_dict(orient='records')\n",
    "\n",
    "data_dict = dict(\n",
    "    clinical_question=original_qd_dict[0]['Question'],\n",
    "    evidence_assessment_results=evidence_assessment_results,\n",
    ")\n",
    "\n",
    "quicker._add_data_to_quickerdata_for_test(\n",
    "    stage=QuickerStage.EVIDENCE_ASSESSMENT,\n",
    "    default_value=data_dict,\n",
    ")\n",
    "\n",
    "\n",
    "quicker.update_input_data(dict(supplementary_information=supplementary_information))\n",
    "\n",
    "print(quicker)\n",
    "# print(quicker.quicker_data)\n",
    "print(quicker.quicker_data.check_stage_state())\n",
    "print(quicker.quicker_data.not_none_data)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_result = quicker.form_recommendation(\n",
    "    evidence_assessment_results=quicker.quicker_data.evidence_assessment_results\n",
    "    )\n",
    "\n",
    "\n",
    "quicker.quicker_data.update_data(dict(final_result=final_result))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "quicker.quicker_data.to_json(YOUR_RECOMMENDATION_FORMATION_PATH)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "quicker",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
